High-throughput RNAi screening identifies a role for TNK1 in growth and survival of pancreatic cancer cells

Molecular Cancer Research

Volumn 9, Issue 6, 2011, Pages 724-732

  Henderson, Meredith C ^a   Gonzales, Irma M ^a   Arora, Shilpi ^a   Choudhary, Ashish ^a   Trent, Jeffrey M ^a   Von Hoff, Daniel D ^a   Mousses, Spyro ^a   Azorsa, David O ^a  

^a TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; K RAS PROTEIN; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE TNK1; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE SILENCING; GENETIC SCREENING; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DEOXYCYTIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FETAL PROTEINS; GENE SILENCING; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PANCREATIC NEOPLASMS; PROTEIN-TYROSINE KINASES; RNA, SMALL INTERFERING;

EID: 79959228539     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-10-0436     Document Type: Article

References (29)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-49.
2. Carmichael J, Fink U, Russell RC, Spittle MF, Harris AL, Spiessi G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996;73:101-5. (Pubitemid 26026268)
3. Azorsa DO, Gonzales IM, Basu GD, Choudhary A, Arora S, Bisanz KM, et al. Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J Transl Med 2009;7:43.
4. Arora S, Bisanz KM, Peralta LA, Basu GD, Choudhary A, Tibes R, et al. RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells. Gynecol Oncol 2010;118:220-7.
5. Arora S, Gonzales IM, Hagelstrom RT, Beaudry C, Choudhary A, Sima C, et al. RNAi phenotype profiling of kinases identifies potential therapeutic targets in Ewing's sarcoma. Mol Cancer 2010;9:218.
6. Hoehn GT, Stokland T, Amin S, Ramírez M, Hawkins AL, Griffin CA, et al. Tnk1: a novel intracellular tyrosine kinase gene isolated from human umbilical cord blood CD34+/Lin-/CD38- stem/progenitor cells. Oncogene 1996;12:903-13. (Pubitemid 26072276)
7. Hoare K, Hoare S, Smith OM, Kalmaz G, Small D, Stratford May W. Kos1, a nonreceptor tyrosine kinase that suppresses Ras signaling. Oncogene 2003;22:3562-77. (Pubitemid 36765316)
8. Hoare S, Hoare K, Reinhard MK, Lee YJ, Oh SP, May WS Jr. Tnk1/ Kos1 knockout mice develop spontaneous tumors. Cancer Res 2008;68:8723-32.
9. Azoitei N, Brey A, Busch T, Fulda S, Adler G, Seufferlein T. Thirty-eight-negative kinase 1 (TNK1) facilitates TNFalpha-induced apoptosis by blocking NF-kappaB activation. Oncogene 2007;26:6536-45. (Pubitemid 47530600)
10. Lierman E, Van Miegroet H, Beullens E, Cools J. Identification of protein tyrosine kinases with oncogenic potential using a retroviral insertion mutagenesis screen. Haematologica 2009;94:1440-4.
11. Gu TL, Cherry J, Tucker M, Wu J, Reeves C, Polakiewicz RD. Identification of activated Tnk1 kinase in Hodgkin's lymphoma. Leukemia 2010;24:861-5.
12. Liu N, Furukawa T, Kobari M, Tsao MS. Comparative phenotypic studies of duct epithelial cell lines derived from normal human pancreas and pancreatic carcinoma. Am J Pathol 1998;153:263-9. (Pubitemid 28317529)
13. Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol 2000;157:1623-31.
14. Collins PJ, Hennessy LK, Leibelt CS, Roby RK, Reeder DJ, Foxall PA. Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: the AmpFlSTR Identifiler PCR Amplification Kit. J Forensic Sci 2004;49:1265-77. (Pubitemid 39453184)
15. Birmingham A, Selfors LM, Forster T, Wrobel D, Kennedy CJ, Shanks E, et al. Statistical methods for analysis of high-throughput RNA interference screens. Nat Methods 2009;6:569-75.
16. Song D, Chaerkady R, Tan AC, García-García E, Nalli A, Suáarez-Gauthier A, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. Mol Cancer Ther 2008;7:3275-84.
17. Rosales JL, Lee KY. Extraneuronal roles of cyclin-dependent kinase 5. Bioessays 2006;28:1023-34. (Pubitemid 44570451)
18. Lee CS, Charalambous D. Immunohistochemical localisation of the c-fos oncoprotein in pancreatic cancers. Zentralbl Pathol 1994;140:271-5.
19. Schneider M, Buchler P, Giese N, Giese T, Wilting J, Büuchler MW, et al. Role of lymphangiogenesis and lymphangiogenic factors during pancreatic cancer progression and lymphatic spread. Int J Oncol 2006;28:883-90.
20. von Forstner C, Egberts JH, Ammerpohl O, Niedzielska D, Buchert R, Mikecz P, et al.Gene expression patterns and tumor uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an orthotopic mouse xenotransplantation model of pancreatic cancer. J Nucl Med 2008;49:1362-70.
21. Koizumi K, Tanno S, Nakano Y, Habiro A, Izawa T, Mizukami Y, et al. Activation of p38 mitogen-activated protein kinase is necessary for gemcitabine-induced cytotoxicity in human pancreatic cancer cells. Anticancer Res 2005;25:3347-53. (Pubitemid 41105211)
22. Lee KH, Hyun MS, Kim JR. Growth factor-dependent activation of the MAPK pathway in human pancreatic cancer: MEK/ERK and p38 MAP kinase interaction in uPA synthesis. Clin Exp Metastasis 2003;20:499-505. (Pubitemid 37297177)
23. Adachi S, Yasuda I, Nakashima M, Yamauchi T, Yamauchi J, Natsume H, et al. HSP90 inhibitors induce desensitization of EGF receptor via p38 MAPK-mediated phosphorylation at Ser1046/1047 in human pancreatic cancer cells. Oncol Rep 2010;23:1709-14.
24. Sawai H, Funahashi H, Okada Y, Matsuo Y, Sakamoto M, Yamamoto M, et al. Interleukin-1alpha enhances IL-8 secretion through p38 mitogen-activated protein kinase and reactive oxygen species signaling in human pancreatic cancer cells. Med Sci Monit 2005;11:BR343-50.
25. Katoh M. Transcriptional mechanisms of WNT5A based on NF-kappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med 2009;23:763-9.
26. Schreiner B, Baur DM, Fingerle AA, Zechner U, Greten FR, Adler G, et al. Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- transgenic mice. Genes Chromosomes Cancer 2003;38:240-8. (Pubitemid 37259641)
27. Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, et al. Genetic profile of 22 pancreatic carcinoma cell lines. Analysis of K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 2001;439:798-802.
28. Sipos B, Moser S, Kalthoff H, Torok V, Lohr M, Kloppel G. A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards the establishment of an in vitro research platform. Virchows Arch 2003;442:444-52. (Pubitemid 36718311)
29. Smit VT, Boot AJ, Smits AM, Fleuren GJ, Cornelisse CJ, Bos JL. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988;16:7773-82.